Journal of Clinical & Experimental OncologyISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Clin Exp Oncol Vol: 2 Issue: 4

Survivin and Livin with Angiogenesis in Cancer

Mutlu Dogan*
Ankara Numune Training and Research Hospital, Dept of Medical Oncology, Ankara, Turkey
Corresponding author : Mutlu Dogan
Associate Professor, Ankara Numune Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey,
+903125084600; Fax: +903125084914
E-mail: [email protected]
Received: September 09, 2013 Accepted: November 28, 2013 Published: December 16, 2013
Citation: Dogan M (2013) Survivin and Livin with Angiogenesis in Cancer. J Clin Exp Oncol 2:4. doi:10.4172/2324-9110.1000115


Survivin and Livin with Angiogenesis in Cancer

Tumor promotion and progression depends on a complex interaction between cellular signaling pathways, apoptosis, angiogenesis and other mechanisms. Understanding these mechanisms and their interactions led to the development of targeted therapies such as antiangiogenic agents and mTOR inhibitors in cancer. In recent years, inhibitors of apoptosis proteins (IAP) like survivin and livin seem promising as new targets for cancer therapy. In this report, the role of survivin and livin with angiogenesis will be discussed.

Keywords: Survivin; Livin; Cancer

Track Your Manuscript

Recommended Conferences

World Congress on Women Oncology & Care

Tokyo, Japan

World Cancer, Oncology and Therapeutics Congress

Paris, France

Share This Page

Media Partners